pp-006 Injection 500mg, 1g
Dossier type
CTD
Dossier status
Under development
Country of origin
China
GMP approvals
China
Comments
Phase 3 antibacterial, in the same drug class as cefiderocol (other cephalosporins and penems). Indication: Complicated urinary tract infection (monotherapy). Phase 1 indication: Pulmonary infection (monotherapy).
Manufacturer #17216
Global developer of innovative drugs in oncology, metabolic, autoimmune, and cardiovascular diseases, with 14 in-house products and multiple partnerships. Over 5,000 R&D staff across global centers and strong IP, clinical pipeline, and high-standard manufacturing.
Manufacturer usually replies in 41 days